The stock is currently trading higher by 66.25% or $1.06 following the positive news, hitting $2.66 per share at the time of us publishing this article.
Acasti Pharma Inc. is a Canada-based biopharmaceutical firm focused on the research, development and commercialization of new krill oil forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. The company has a market cap of $17.12 million. The Firm is engaged in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It currently has negative earnings. CaPre, the Company’s prescription drug candidate, is a purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia.